Jump to content

Pfizer Reports Encouraging Results From Phase II Lung Cancer


RandyW

Recommended Posts

Pfizer Reports Encouraging Results From Phase II Lung Cancer Trial

Posted on: Tuesday, 16 September 2008, 12:00 CDT

Pfizer has announced updated safety and efficacy results from a Phase II, randomized, non-comparative study surrounding its investigational compound, CP-751,871, in patients with non-small cell lung cancer.

Results from a Phase II, randomized, non-comparative study showed that 54% of patients with stage III/IV treatment-naive NSCLC receiving the combination CP-751,871 plus carboplatin and paclitaxel (n=97) experienced objective responses. The response rate was 41% in patients treated with carboplatin and paclitaxel alone (n=53).

In addition, 78% of a subset of patients with squamous cell carcinoma (n=9) and 57% of a subset of patients with adenocarcinoma (n=28) receiving 20mg/kg of CP-751,871 plus carboplatin and paclitaxel experienced objective responses.

Response rates were 46% and 25%, respectively, for squamous cell (n=12) and adenocarcinoma patients (n=20) receiving carboplatin and paclitaxel alone. No response advantage with CP-751,871 was seen in a subset of patients with undifferentiated tumors.

Patients who received CP-751,871 20mg/kg showed the greatest improvement in progression-free survival (PFS). PFS was defined as either the length of time before the cancer progressed or death.

Antonio Gualberto, director and global clinical leader (oncology), Pfizer global R&D, said: "These data provide greater insight into the potential relationship between tumor histology and response to CP-751,871 observed in the clinical studies. Furthermore, the results support the global Phase III clinical trial program for CP-751,871 in NSCLC."

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.